Skip to main content

Research Repository

Advanced Search

All Outputs (11)

Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data (2019)
Journal Article
Varyani, F., Argyriou, K., Phillips, F., Tsakiridou, E., & Moran, G. W. (2019). Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. Drug Design, Development and Therapy, 13, 4091-4105. https://doi.org/10.2147/dddt.s182891

Recent advances in the understanding of the pathophysiology of ulcerative colitis (UC) have led to the expansion of our therapeutic arsenal. Conventional treatment options, including aminosalicylates, corticosteroids, thiopurines, and calcineurin inh... Read More about Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data.

Physical activity and fatigue in adults with Inflammatory Bowel Disease (IBD): a systematic review (2019)
Journal Article
Radford, S. J., Janiszewski, H., & Moran, G. W. (2019). Physical activity and fatigue in adults with Inflammatory Bowel Disease (IBD): a systematic review. Gastrointestinal Nursing, 17(9), 16-21. https://doi.org/10.12968/gasn.2019.17.9.16

Background: Fatigue is frequently reported in inflammatory bowel disease (IBD). IBD has been shown to have an impact on, and be impacted by, physical activity levels in IBD patients, Yet, to date, there have been no systematic reviews considering the... Read More about Physical activity and fatigue in adults with Inflammatory Bowel Disease (IBD): a systematic review.

Gastrointestinal peptides and small bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn’s disease (2019)
Journal Article
Khalaf, A., Hoad, C. L., Menys, A., Nowak, A., Radford, S., Taylor, S. A., …Moran, G. W. (2020). Gastrointestinal peptides and small bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn’s disease. American Journal of Clinical Nutrition, 111(1), 131–140. https://doi.org/10.1093/ajcn/nqz240

Background Crohn's disease (CD) patients suffer postprandial aversive symptoms, which can lead to anorexia and malnutrition. Changes in the regulation of gut hormones and gut dysmotility are believed to play a role. Objectives This study aimed t... Read More about Gastrointestinal peptides and small bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn’s disease.

Infliximab induction regimens in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis (2019)
Journal Article
Sebastian, S., Myers, S., Argyriou, K., Martin, G., Los, L., Fiske, J., …Raine, T. (2019). Infliximab induction regimens in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis. Alimentary Pharmacology and Therapeutics, 50(6), 675-683. https://doi.org/10.1111/apt.15456

Background: Accelerated induction regimens of infliximab have been proposed to improve response rates in patients with steroid refractory acute severe colitis. Aims: We aimed to determine differences in outcome for acute severe ulcerative colit... Read More about Infliximab induction regimens in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis.

Practice pattern variability in the management of acute severe colitis: A UK provider survey (2019)
Journal Article
Sebastian, S., Lisle, J., Subramanian, S., Dhar, A., Shenoy, A., Limdi, J., …Kennedy, N. A. (2019). Practice pattern variability in the management of acute severe colitis: A UK provider survey. Frontline Gastroenterology, https://doi.org/10.1136/flgastro-2019-101277

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. Introduction: Lack of comparative trial data on dosing regimens of infliximab in patients with acute severe ulcerative colitis (ASUC) failing... Read More about Practice pattern variability in the management of acute severe colitis: A UK provider survey.

Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study (2019)
Journal Article
Snowden, J. A., Hawkey, C., Hind, D., Swaby, L., Mellor, K., Emsley, R., …European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP). (2019). Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterology, 19, Article 82. https://doi.org/10.1186/s12876-019-0992-2

Background Intestinal inflammation in Crohn’s disease (CD) is caused by mucosal immune system reactivity to luminal antigen and results in debilitating symptoms, reduced quality of life, impaired work productivity and significant health care costs.... Read More about Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study.

Reduced skeletal muscle protein balance in paediatric Crohn’s disease (2019)
Journal Article
Davies, A., Nixon, A., Muhammed, R., Tsintzas, K., Kirkham, S., Stephens, F. B., & Moran, G. W. (2020). Reduced skeletal muscle protein balance in paediatric Crohn’s disease. Clinical Nutrition, 39(4), 1250-1257. https://doi.org/10.1016/j.clnu.2019.05.017

Background and Aims An inability to respond to nutrition could be implicated in low muscle mass in Crohn’s disease. We aim to determine skeletal muscle metabolic response to feeding in Crohn’s disease and healthy volunteers. Methods Twenty asymp... Read More about Reduced skeletal muscle protein balance in paediatric Crohn’s disease.

Evolution of treatment targets in Crohn’s disease (2019)
Journal Article
White, J. R., Jairath, V., & Moran, G. W. (2019). Evolution of treatment targets in Crohn’s disease. Best Practice and Research: Clinical Gastroenterology, 38-39, 1-9. https://doi.org/10.1016/j.bpg.2019.02.001

Crohn’s disease is a chronic relapsing and remitting inflammatory disorder of the gastrointestinal tract, associated with significantly morbidity due to both symptoms and complications that have a considerable detrimental impact on a patient’s qualit... Read More about Evolution of treatment targets in Crohn’s disease.

Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease (2019)
Journal Article
Shivaji, U. N., Sharratt, C. L., Thomas, T., Smith, S. C., Iacucci, M., Moran, G. W., …Bhala, N. (2019). Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 49(6), 664-680. https://doi.org/10.1111/apt.15097

Background: Biological therapy is currently widely used to treat inflammatory bowel disease (IBD). Infliximab, adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF monoclonal antibodies are increasingly used. Anti-T... Read More about Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.

Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? A systematic review (2019)
Journal Article
Simon, E. G., Wardle, R., Thi, A. A., Eldridge, J., Samuel, S., & Moran, G. W. (2019). Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? A systematic review. Intestinal Research, 17(2), 160-170. https://doi.org/10.5217/ir.2018.00114

Fecal calprotectin (FC) is a highly sensitive disease activity biomarker in inflammatory bowel disease. However, there are conflicting reports on whether the diagnostic accuracy in Crohn’s disease is influenced by disease location. The aim of this st... Read More about Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? A systematic review.